News for Gilead Sciences, Inc. (GIS.DE)

**media[654537]**

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ETCompany ParticipantsDaniel P.

Key Takeaways: Gilead Sciences faces a temporary setback due to a clinical hold by the FDA on their experimental HIV drugs. Despite challenges, analysts

Gilead Sciences (GILD) has announced that its weekly oral HIV treatment study, involving the 1720/4182 combination, has been put on clinical hold. This decision

Gilead Sciences, Inc. (GILD) experienced a 2% decline in its stock price, reaching $111.14, following news that the U.S. Food and Drug Administration (FDA) has

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 m

Summary On May 30, 2025, Gilead Sciences Inc (GILD) announced the opening of the Bay Area Young Survivors Breast Cancer Memorial Garden in San Francisco's Golde

NORTHAMPTON, MA / ACCESS Newswire / May 30, 2025 / Gilead Sciences:We recently commemorated the opening of the Bay Area Young Survivors Breast Cancer Memorial G

As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. The following biotech companies are awaiting potential approvals in June 2025.

Gilead Sciences, Inc. (NASDAQ:GILD) Bernstein Annual Strategic Decisions Conference May 29, 2025 2:30 PM ETCompany ParticipantsDan O’Day - Chairman and...

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

**media[638992]**

**media[638490]**

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more about GILD stock here.

Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major breakthrough in treating metastatic triple-negative breast cancer (mTNBC).

Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major breakthrough in treating metastatic triple-negative breast cancer (mTNBC). Trodelvy (sacituzumab govitecan-hziy) demonstrated a significant and meaningful improvement in progression-free survival compared to chemotherapy in first-line mTNBC patients who cannot receive immunotherapy. This marks the first substantial progress in over […]

Key Takeaways: Gilead Sciences' Trodelvy shows promise in early-stage treatment of triple-negative breast cancer. Analysts forecast Gilead's stock price

Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. GILD is only purchasing HOOK’s antiviral programs, specifically the “HB-400” & “HB-500”. The company first […]